Among them, rhein exhibited significant anti-proliferative activity, superior to carboplatin, with an IC₅₀ value of 72.4 ± 3.7 μM against CAL-27 cells...Moreover, rhein not only activates the mitochondrial-mediated apoptosis signaling pathway (Bax/Bcl-2/cytochrome C/cleaved caspase-3) but also highly activates the expression level of the DNA damage protein γ-H2AX. This study provides new insights into the development of natural anthraquinone compounds as promising candidates for oral cancer therapies.

The patient received 3 cycles of gemcitabine plus carboplatin but experienced rapid clinical deterioration. This case underscores that HAL may mimic nonresolving pneumonia and that normal AFP does not exclude the diagnosis; early biopsy and a targeted immunohistochemical panel are essential for timely recognition of this lethal entity.

GA can be effective in preventing follicle cell damage caused by CP in the ovary.

A library of 16 novel cyclic or acyclic chalcones was designed and synthesized, incorporating substituted heterocyclic rings (pyrrole or pyridine) or nitrogen mustard...Additionally, in silico ADMET screening showed that OH16 exhibits favorable predicted drug-likeness properties. These findings suggest that thienyl-pyridine-based chalcones may serve as promising lead compounds against CRPC; thus, further in vitro and in vivo studies are warranted.

Despite adjuvant carboplatin, paclitaxel, and bevacizumab followed by maintenance therapy, she developed platinum-resistant progression with peritoneal and nodal disease and is currently receiving additional systemic therapy with poor response. This case highlights the potential for malignant transformation in benign-appearing SCT-NOS and underscores the importance of counseling patients on the rare risk of recurrence and the need for novel therapeutic strategies in recurrent disease. Integration of clinical, pathologic, and molecular data may improve risk stratification and management of this rare tumor.

These data indicate that the immune contexture is a critical factor in the response to AC chemotherapy and provides a framework for selecting more effective and less toxic therapies for patients with TNBC.

Mechanistic studies demonstrated that ICAld exerts significant adjunctive antitumor effects both in vitro and in vivo in a dose-dependent manner in mouse models; it acts by activating the aryl hydrocarbon receptor (AHR)/cytochrome P450 family 1 subfamily A member 1 (CYP1A1)/reactive oxygen species (ROS) axis, inhibiting the phosphatidylinositol 3-kinase (PI3K)/AKT/mechanistic target of rapamycin (mTOR) signaling pathway, promoting apoptosis, and synergizing with cyclophosphamide. An aryl hydrocarbon receptor antagonist reversed both the chemosensitizing and intestinal protective effects of L. reuteri HG001 and ICAld. This study elucidates a microbiota-mediated mechanism in DLBCL and supports L. reuteri HG001 as a probiotic adjuvant to enhance therapy while reducing toxicity.

We present a case of a 66-year-old female with de novo metastatic NSCLC harboring an EGFR mutation, RET rearrangement, and ERBB2 amplification, who experienced transformation to SCLC while on osimertinib. Subsequently, she exhibited primary refractory disease to both first-line platinum doublet with immunotherapy and second-line lurbinectedin...The patient had minimal side effects and obtained a partial response with a progression-free survival (PFS) of 13.1 months, better than historically poor prognosis seen in transformed SCLC. This case underscores the potential role of human epidermal growth factor receptor 2 (HER-2) directed therapies, such as T-DXd, in transformed SCLC.

To our knowledge, this is the first report to demonstrate the efficacy of carboplatin, pemetrexed, and amivantamab against LMD progression after osimertinib therapy, suggesting that this regimen may be a therapeutic option for patients with LMD, including those with symptomatic disease. Nevertheless, further studies are warranted to confirm efficacy in this population.

We report a 65-year-old patient with heavily pretreated, FRα-positive ovarian cancer who developed therapy-related myelodysplastic syndrome with increased blasts (MDS-IB2, DNMT3A-mutated) during therapy with MIRV in combination with carboplatin having received prior PARPi maintenance therapy. This case demonstrates that MIRV can be safely and effectively administered alongside azacitidine, providing clinically meaningful tumor control without compromising hematologic outcomes. These findings support the concurrent management of ovarian cancer and therapy-related MDS as a viable and underutilized treatment approach in a highly challenging clinical setting.

P2, N=30, Not yet recruiting, Sichuan University | Initiation date: Dec 2025 --> Oct 2026

P2, N=242, Active, not recruiting, University of Birmingham | Trial primary completion date: Nov 2024 --> Oct 2025